Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus PIMTREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus PIMTREA.
CYCLESSA vs PIMTREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life of 2.5 to 4 hours; prolonged in renal impairment (up to 6–12 hours in severe impairment).
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Primarily renal (approximately 70% as unchanged drug), with biliary/fecal excretion accounting for the remainder. Less than 5% metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive